The architecture powering Zero Trust at the edge

Tern plc

The shift to Zero Trust security has placed a new spotlight on the most fundamental yet overlooked layer of the digital ecosystem: device identity. For enterprises managing vast fleets of connected assets, the moment of onboarding is no longer a technical footnote, it is the critical juncture where long-term trust, compliance, and resilience begin.

What has long been treated as an administrative step in the supply chain has now become a strategic control point. Weak or reused device identities have been the unseen entry point for some of the most serious operational breaches, from energy grid outages to compromised medical systems. Yet, the tide is turning. Advances in automated identity provisioning now enable enterprises to establish verifiable trust at the very edge, embedding security directly during manufacturing and onboarding rather than layering it on afterwards.

At the centre of this evolution is Device Authority’s KeyScaler® platform, which automates the creation and management of strong, unique device identities at industrial scale. Each identity can be anchored in hardware through Trusted Platform Modules or secure elements, or dynamically generated via Dynamic Device Key Generation when such components are absent.

The true strength of Zero Trust, however, lies in the ongoing validation of identity rather than its initial establishment. Device Authority’s partnership with Olympus integrates these trust anchors into identity and access management frameworks where policies continuously adapt to device health, behaviour, and operational context.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Search